儿童脓毒性休克后疾病严重程度与家庭结局的关联
该研究为Life After Pediatric Sepsis Evaluation前瞻性队列的二次分析,纳入12个美国学术型PICU中<18岁、社区获得性脓毒性休克需血管活性-正性肌力支持及有创或无创通气的患儿。276名照护者在基线及入PICU后1、3、6、12个月报告心理困扰、家庭功能及患儿健康相关生活质量。心理困扰患病率初期下降后升至15.3%,家庭功能障碍患病率稳步升至12个月30.9%。校正年龄、医疗复杂度和免疫抑制后,较高儿科死亡风险评分、血管活性-正性肌力评分及更长PICU和住院时间与1个月时更严重照护者困扰相关;较高儿科 logistic 器官功能障碍评分、更长通气时间和更长PICU住院与1、3、6个月家庭功能障碍几率更低相关;照护者困扰与患儿健康相关生活质量较基线下降相关。作者认为存活后持续心理社会支持可能使患儿和家庭获益。
要点
- 儿童脓毒性休克后12个月内家庭功能障碍患病率稳步升至30.9%,照护者心理困扰患病率初期下降后升至15.3%。
- 校正年龄、医疗复杂度和免疫抑制后,较高儿科死亡风险评分、血管活性-正性肌力评分及更长PICU和住院时间与1个月时更大照护者困扰相关。
- 较高儿科 logistic 器官功能障碍评分、更长通气时间和更长PICU住院与1、3、6个月家庭功能障碍几率更低相关(平均PELOD vs 新发6个月功能障碍:OR 0.73,95%CI 0.55-0.96)。
- 照护者心理困扰与患儿健康相关生活质量较基线下降相关:1个月OR 2.92(95%CI 1.27-6.75)、3个月OR 2.34(95%CI 1.01-5.42)、12个月OR 3.94(95%CI 1.54-10.06)。
- 作者认为儿童脓毒性休克存活后持续心理社会支持可能使患儿和家庭获益。
适用人群与场景
- 纳入:12个美国学术型PICU中<18岁、社区获得性脓毒性休克需血管活性-正性肌力支持及有创或无创通气的患儿及其照护者。
- 场景:PICU入院后1年内随访。
研究设计与关键结果
- 设计:Life After Pediatric Sepsis Evaluation前瞻性队列研究的二次分析,12个美国学术型PICU,276名照护者。
- 主要结局:照护者心理困扰(Brief Symptom Inventory)、家庭功能(Family Assessment Device)、患儿健康相关生活质量(Pediatric Quality of Life Inventory、Functional Status II-Revised)在基线及1、3、6、12个月评估。
- 心理困扰患病率初期下降后升至15.3%;家庭功能障碍患病率稳步升至12个月30.9%。
- 多变量logistic回归校正患儿年龄、医疗复杂度和免疫抑制后,较高儿科死亡风险评分、血管活性-正性肌力评分及更长PICU和住院时间与1个月时更大照护者困扰相关。
- 较高儿科logistic器官功能障碍评分、更长通气时间和更长PICU住院与1、3、6个月家庭功能障碍几率更低相关(平均PELOD vs 新发6个月功能障碍:OR 0.73,95%CI 0.55-0.96)。
- 照护者困扰与患儿健康相关生活质量较基线下降相关:1个月OR 2.92(95%CI 1.27-6.75)、3个月OR 2.34(95%CI 1.01-5.42)、12个月OR 3.94(95%CI 1.54-10.06)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,儿童脓毒性休克存活后持续心理社会支持可能使患儿和家庭获益。
- 照护者心理困扰与患儿健康相关生活质量下降相关,提示可关注照护者心理状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: It is unknown which families are at risk for poor outcomes following a child's critical illness.
OBJECTIVES: To evaluate if pediatric septic shock severity is associated with caregiver distress and family dysfunction throughout the year postadmission and if caregiver outcomes are associated with child health-related quality of life (HRQL).
DESIGN SETTING AND PARTICIPANTS: Secondary analysis of the Life After Pediatric Sepsis Evaluation prospective cohort study among children less than 18 years old with community-acquired septic shock requiring vasoactive-inotropic support and invasive or noninvasive ventilation in 12 academic U.S. PICUs.
MAIN OUTCOMES AND MEASURES: Caregivers reported personal psychologic distress (Brief Symptom Inventory), family functioning (Family Assessment Device), and child HRQL (Pediatric Quality of Life Inventory, Functional Status II-Revised) at baseline and 1, 3, 6, and 12 months following PICU admission.
RESULTS: Among 276 caregivers, psychologic distress prevalence initially decreased then rose to 15.3%, whereas prevalence of family dysfunction increased steadily to 30.9% at 12 months. On multivariable logistic regression adjusting for patient age, medical complexity, and immunosuppression, higher Pediatric Risk of Mortality and vasoactive-inotropic scores and longer PICU and hospital stay were associated with greater caregiver distress at 1 month. Higher Pediatric Logistic Organ Dysfunction (PELOD) score, longer ventilation, and longer PICU stay were associated with lower odds of family dysfunction at 1, 3, and 6 months (average PELOD vs new 6-mo dysfunction: odds ratio [OR], 0.73 [95% CI, 0.55-0.96]). Caregiver distress was associated with child HRQL decline from baseline to 1 month (OR, 2.92 [1.27-6.75]), 3 months (OR, 2.34 [1.01-5.42]), and 12 months (OR, 3.94 [1.54-10.06]).
CONCLUSIONS AND RELEVANCE: Family dysfunction becomes increasingly prevalent over the year following pediatric septic shock and is less likely following higher severity illness. Caregiver psychologic distress is associated with worse child HRQL. Both patients and families may benefit from ongoing psychosocial support following survival from pediatric septic shock.
参考来源
- Killien EY, Zimmerman JJ, Di Gennaro JL, et al. Association of Illness Severity With Family Outcomes Following Pediatric Septic Shock. Crit Care Explor. 2022. PMID: 35733611. doi:10.1097/CCE.0000000000000716
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。